PolyPid Advances Trial for Infection Prevention
Company Announcements

PolyPid Advances Trial for Infection Prevention

PolyPid (PYPD) has released an update.

PolyPid Ltd. has discussed the rising challenge of surgical site infections (SSIs) and highlighted its ongoing SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing SSIs in abdominal surgeries. The trial has currently enrolled about 250 of the planned 600 patients, with interim analysis expected after 400 patients complete a 30-day follow-up, and top-line results anticipated in early 2025. The company’s D-PLEX100 product, which releases antibiotics over 30 days, could improve patient outcomes and reduce healthcare costs associated with SSIs.

For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPolyPid Announces $8.25 Million Share Sale Plan
TheFlyCraig-Hallum bullish on PolyPid, initiates with a Buy
TheFlyPolyPid initiated with a Buy at Craig-Hallum
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App